4,4-Dimethyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydronaphthalen-1(2H)-one → 7-{2-[4-(2-hydroxyethylamino)piperidin-1-yl]thiazol-4-yl}-4,4-dimethyl-3,4-dihydro-2H-naphthalen-1-one

HRID 1401775Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1401775
Br[C:2]1[N:3]=[C:4]([N:7]2[CH2:12][CH2:11][CH:10]([NH:13][CH2:14][CH2:15][OH:16])[CH2:9][CH2:8]2)[S:5][CH:6]=1.[CH3:17][C:18]1([CH3:38])[C:27]2[C:22](=[CH:23][C:24](B3OC(C)(C)C(C)(C)O3)=[CH:25][CH:26]=2)[C:21](=[O:37])[CH2:20][CH2:19]1>>[OH:16][CH2:15][CH2:14][NH:13][CH:10]1[CH2:11][CH2:12][N:7]([C:4]2[S:5][CH:6]=[C:2]([C:24]3[CH:23]=[C:22]4[C:27]([C:18]([CH3:38])([CH3:17])[CH2:19][CH2:20][C:21]4=[O:37])=[CH:26][CH:25]=3)[N:3]=2)[CH2:8][CH2:9]1

Komponenten

3

Edukt 2

HCID 673232734,4-Dimethyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydronaphthalen-1(2H)-oneHCID 673233402-(1-(4-Bromothiazol-2-yl)piperidin-4-ylamino)ethanol

Produkt 1

HCID 673769197-{2-[4-(2-hydroxyethylamino)piperidin-1-yl]thiazol-4-yl}-4,4-dimethyl-3,4-dihydro-2H-naphthalen-1-one

Versuchsvorschrift

The preparation is carried out as already described above starting from 100 mg (0.27 mmol) of 2-[1-(4-bromothiazol-2-yl)piperidin-4-ylamino]ethanol (preparation already described above) and 88 mg (0.29 mmol) of 4,4-dimethyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-naphthalen-1-one. The product was purified by means of flash chromatography on silica gel.

Aufarbeitung

  1. custompreparation
  2. customThe product was purified by means of flash chromatography on silica gel

Quellen und Nachweise

ORD-Eintrag
ord-22ed3085e3eb4814aa37e581afddd375
Quelldatensatz
uspto-grants-2014_12
Patentnummer
US08907098B2

Notizen zur Reaktion

Wird geladen…